Clinical Scorecard: Evaluation and risk assessment of PI-RADS v2.1 categories 3–5 lesions through amide proton transfer imaging

At a Glance

Key Highlights

• PI-RADS v2.1 categories 3–5 lesions have variable rates of clinically significant prostate cancer, with high false positive rates in current multiparametric MRI sequences.
• APTWI provides metabolic imaging by measuring amide proton transfer, reflecting intracellular protein content and pH changes linked to cancer progression.
• Combining APTWI parameters with ADC and PSA density improves risk assessment and correlates with Gleason Score for better early diagnosis and treatment planning.

Guideline-Based Recommendations

Diagnosis

• Use multiparametric MRI including T1WI, T2WI, DWI, DCE, and APTWI sequences for evaluation of prostate lesions.
• Assign PI-RADS v2.1 scores to categorize lesion risk from 1 to 5 based on MRI findings.
• Perform serum PSA and PSA-density measurements prior to MRI.
• Confirm diagnosis with biopsy or surgery within 2 weeks after MRI for pathological Gleason Score determination.

Management

• Monitor men with low Gleason Score (≤ 6) regularly as per NCCN guidelines.
• Consider aggressive treatment such as surgery or androgen deprivation therapy for clinically significant prostate cancer (GS ≥ 3 + 4).
• Use combined imaging parameters (APTWI, ADC, PSAD) to refine risk stratification and guide clinical decision-making to minimize unnecessary procedures.

Monitoring & Follow-up

• Perform regular PSA and PSA-density assessments in men under surveillance.
• Repeat multiparametric MRI including APTWI as needed to monitor lesion progression or response to treatment.

Risks

• High false positive rates in PI-RADS category 3 lesions may lead to unnecessary biopsies or treatments.
• Poor image quality or incomplete imaging sequences can impair diagnostic accuracy.
• Delay in biopsy or pathological confirmation may affect timely management.

Patient & Prescribing Data

Men with suspected prostate cancer and PI-RADS v2.1 category 3–5 lesions undergoing multiparametric MRI and biopsy

APTWI combined with ADC and PSAD enhances prediction of aggressive prostate cancer, correlates with Gleason Score, and supports tailored treatment strategies.

Clinical Best Practices

• Ensure high-quality multiparametric MRI acquisition including APTWI with patient preparation (bowel emptying, moderate bladder filling).
• Use dual-radiologist blinded assessment to improve diagnostic consistency and accuracy.
• Select region of interest (ROI) carefully avoiding necrosis, calcification, hemorrhage, and lesion edges for accurate parameter measurement.
• Integrate metabolic imaging data (APTmax, APTmean, APTmin) with conventional MRI parameters and serum PSA metrics for comprehensive risk evaluation.
• Apply NCCN guidelines for treatment decisions based on Gleason Score and imaging findings.

References

• National Comprehensive Cancer Network (NCCN) Guidelines
• PI-RADS v2.1 Prostate Imaging Reporting and Data System